To reduce treatment delays, pathologists should initiate biomarker testing reflexively. Waiting for a medical oncologist to order tests at a first visit is a system failure, wasting critical time and risking the need to retrieve archived samples.

Breast cancer specialists advocate for patients to meet the entire care team before surgery to create a comprehensive plan and reduce anxiety. However, insurance carriers often create administrative and financial barriers that prevent these coordinated, upfront consultations, leading to a more fragmented and stressful patient experience.

Clinicians ordering "NGS for lung" often misunderstand that Next-Generation Sequencing alone does not cover all actionable biomarkers, such as PD-L1 or HER2. This requires pathologists to interpret the clinician's intent and order a more comprehensive and appropriate test panel.

Patients with complex illnesses often become "medical nomads," shuffling between specialists who only view problems through their narrow training lens. Effective treatment requires a coordinated, team-based approach, which is largely absent in private practice, leaving patients to manage their own care.

Data shows an average two-week delay occurs between a lung cancer patient's biopsy and the ordering of essential biomarker tests. This administrative gap, separate from the diagnostic process itself, is a major bottleneck that postpones critical treatment decisions.

With highly effective neoadjuvant therapies now available, the surgeon's role in muscle-invasive bladder cancer is evolving. They are moving from being the primary decider and treater to being a key manager of a 'perioperative bundle,' where their first goal is often to get patients to medical oncology for systemic treatment.

Historically, intratumoral therapy was limited by the physical difficulty of reaching tumors. The rise of a new discipline, Interventional Oncology, has largely solved this access problem. The critical bottleneck is now the lack of drugs specifically designed and optimized for local delivery and sustained retention within the tumor.

While oncologists focus on the low 4% rate of Interstitial Lung Disease (ILD) from neoadjuvant TDXD, surgeons worry this complication could prevent patients from reaching potentially curative surgery, drawing parallels to issues seen with neoadjuvant immunotherapy.

A Management Services Organization (MSO) model's success is geographically dependent. In dense markets like Florida, providers have leverage over clinicians. In isolated markets like Las Vegas, individual doctors control patient flow and can resist cost-saving directives, undermining the MSO's value proposition.